PMID- 24940065
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140618
LR  - 20211021
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 10
DP  - 2014
TI  - Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by 
      both alpha-synucleinopathy and tauopathy.
PG  - 1003-9
LID - 10.2147/NDT.S64015 [doi]
AB  - Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is 
      indicated for use in early and advanced Parkinson's disease (PD). RTG patch has 
      many potential advantages due to the immediacy of onset of the therapeutic 
      effect. Of note, intestinal absorption is not necessary and drug delivery is 
      constant, thereby avoiding drug peaks and helping patient compliance. In turn, 
      transdermal RTG seems a suitable candidate in the treatment of atypical 
      Parkinsonian disorders (APS). Fifty-one subjects with a diagnosis of APS were 
      treated with transdermal RTG. The diagnoses were: Parkinson's disease with 
      dementia, multiple system atrophy Parkinsonian type, multiple system atrophy 
      cerebellar type, progressive supranuclear palsy, corticobasal degeneration, Lewy 
      body dementia, and frontotemporal dementia with Parkinsonism. Patients were 
      evaluated by the Unified Parkinson's Disease Rating Scale (UPDRS; part III), 
      Neuropsychiatric Inventory (NPI), and mini-mental state examination (MMSE) and 
      all adverse events (AEs) were recorded. Patients treated with RTG showed an 
      overall decrease of UPDRS III scores without increasing behavioral disturbances. 
      Main AEs were hypotension, nausea, vomiting, drowsiness, tachycardia, and 
      dystonia. On the whole, 15 patients were affected by AEs and seven patients 
      suspended RTG treatment due to AEs. The results show that transdermal RTG is 
      effective with a good tolerability profile. RTG patch could be a good therapeutic 
      tool in patients with APS.
FAU - Moretti, Davide Vito
AU  - Moretti DV
AD  - IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
FAU - Binetti, Giuliano
AU  - Binetti G
AD  - IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
FAU - Zanetti, Orazio
AU  - Zanetti O
AD  - IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
FAU - Frisoni, Giovanni Battista
AU  - Frisoni GB
AD  - IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
LA  - eng
PT  - Journal Article
DEP - 20140605
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC4051815
OTO - NOTNLM
OT  - Parkinson plus
OT  - open label study
OT  - transdermal dopamine agonist
EDAT- 2014/06/19 06:00
MHDA- 2014/06/19 06:01
PMCR- 2014/06/05
CRDT- 2014/06/19 06:00
PHST- 2014/06/19 06:00 [entrez]
PHST- 2014/06/19 06:00 [pubmed]
PHST- 2014/06/19 06:01 [medline]
PHST- 2014/06/05 00:00 [pmc-release]
AID - ndt-10-1003 [pii]
AID - 10.2147/NDT.S64015 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2014 Jun 5;10:1003-9. doi: 10.2147/NDT.S64015. 
      eCollection 2014.